Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biology
biotech
boston blog main
boston top stories
cancer
crispr
crispr therapeutics
crispr-cas9
editas
editas medicine
endeavor
fundings & exits
health
intellia therapeutics
life sciences
national
national blog main
national top stories
p53
peter diamandis
san francisco blog main
san francisco top stories
singularity
singularity university
startups
tc
technology
What
cells
gene
2
×
human
2
×
medicine
new
2
×
biopharmaceutical
called
cancer
cas
celgene
celularity
company
creating
crispr
defect
derived
diamandis
drive
edited
editing
endeavor
fears
flag
focus
founder
genetic
global
guardian
hold
key
known
lab
malfunction
million
myriad
nature
nicknamed
occurs
papers
peter
Language
Current search:
human
×
gene
×
new
×
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@techcrunch.com
6 years ago
With $250 million, Peter Diamandis’ new startup is all about taking stem cells from placentas